推荐产品
等级
analytical standard
质量水平
产品线
VETRANAL®
保质期
limited shelf life, expiry date on the label
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
forensics and toxicology
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F
InChI
1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
InChI key
BCEHBSKCWLPMDN-MGPLVRAMSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
Voriconazole is a second-generation triazole, and is derived from fluconazole. It has a broad and enhanced antifungal spectrum as compared to other older triazoles. It is mostly well tolerated and is available in both oral and intravenous formulations.
应用
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
生化/生理作用
伏立康唑是一种抗真菌药，可抑制麦角固醇的合成。
伏立康唑是用于治疗严重真菌感染的抗真菌药。伏立康唑通过抑制 CYP450 依赖性 14-α甾醇脱甲基酶来抑制麦角固醇合成，从而导致真菌细胞膜中的麦角固醇减少。
It has been used as one of the constituent of YPD (1% yeast extract, 2% peptone, 2% glucose) liquid media.
Voriconazole is an antifungal used to treat serious fungal infections. Voriconazole inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-a sterol demethylase resulting in a depletion of ergosterol in fungal cell membranes.
法律信息
VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 3 Oral - Aquatic Chronic 3 - Carc. 2 - Muta. 2 - Repr. 2 - STOT RE 1 - STOT RE 2 Oral - STOT SE 2 Oral
靶器官
Eyes, Liver,Kidney
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht, Raoul, et al.
The New England Journal of Medicine, 347 (6), 408-415 (2002)
Convergent evolution of calcineurin pathway roles in thermotolerance and virulence in Candida glabrata.
Chen, Ying-Lien, et al.
G3 (Bethesda, Md.), 2 (6), 675- 691 (2012)
Voriconazole: a new triazole antifungal agent.
Saravolatz, Louis D., Leonard B. Johnson, and Carol A. Kauffman.
Clinical Infectious Diseases, 36 (5), 630-637 (2003)
Atsuko Sunada et al.
Ophthalmology, 121(10), 2059-2065 (2014-06-02)
To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Laboratory research. Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro.
Kim Vanstraelen et al.
Antimicrobial agents and chemotherapy, 58(11), 6782-6789 (2014-09-04)
Setting the adequate dose for voriconazole is challenging due to its variable pharmacokinetics. We investigated the impact of hypoalbuminemia (<35 g/liter) on voriconazole pharmacokinetics in adult intensive care unit (ICU) patients treated with voriconazole (20 samples in 13 patients) as
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门